摘要
疫苗的接种、人类卫生意识的提高、抗病毒药物的逐渐开发降低了乙型肝炎病毒(hepatitis B virus,HBV)的感染,但HBV的消除仍是一大难题,因此HBV的精准检出率极为重要。传统的血清标志物HBV DNA和乙肝表面抗原(hepatitis B surface antigen,HBsAg)在准确反映共价闭合环状DNA(covalently closed circular DNA,cccDNA)转录活性与用药检测方面存在一定的局限性。为此,研究者陆续开发出新型HBV血清标志物,如HBV表面抗原、HBV RNA、HBV核心相关抗原、HBV大表面蛋白。基于不同标志物在疾病诊断中的不同参考价值,本文简要对这些标志物的临床应用及面临挑战进行小结,旨在为HBV的高效、准确检出及临床预后提供参考。
Even though the infection of hepatitis B virus(HBV)has been reduced by the vaccination and the improvement of human health awareness,and the gradual development of antiviral drugs.So far,the elimination of HBV is still a serious problem.Hence,the accurate detection rate of HBV is extremely important.The traditional serum makers HBV DNA and hepatitis B surface antigen(HBsAg)have certain limitations in assessing the anti-HBV efficacy and accurately reflecting the transcriptional activity of covalently closed circular DNA(cccDNA).In order to solve this situation,novel HBV serum markers have been developed,such as HBV surface antigen,HBV RNA,HBV core related antigen,and HBV large surface protein.Based on the different reference values of different markers in disease diagnosis,this article briefly summarizes the clinical applications and limitations of these markers,which aims to provide references for the efficient and accurate detection of HBV and clinical prognosis.
作者
刘俊叶
周华
伍晓莉
汪德强
Liu Junye;Zhou Hua;Wu Xiaoli;Wang Deqiang(College of Laboratory Medicine,Chongqing Medical University;Department of Laboratory Medicine,The Second Affiliated Hospital of Chongqing Medical University)
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2022年第12期1432-1435,共4页
Journal of Chongqing Medical University
基金
重庆市自然科学基金重点资助项目(编号:CQYC202003036)
国家传染病重大专项任务级子课题资助项目(编号:2013ZX10002002-003-002)。
